

Ref No. NLL/CS/2013- 308

Dated: 15.05.2013

1. National Stock Exchange of India Limited
'G' Block, Exchange Plaza, Bandra Kurla Complex,
Bandra (East), MUMBAI – 400 051.
2. Bombay Stock Exchange Limited
Phiroze Jeejeebhoy Towers, Dalal Street,
MUMBAI – 400 001.

Sub: Compliance under Clause 41 the Listing Agreement.

Sirs,


Pursuant to Clause 41 of the Listing Agreement, please find enclosed herewith a copy of the Audited Financial Results for the period ended on 31st March, 2013, as approved by the Board of Directors in their meeting held on even date i.e. 15th May, 2013.

Kindly take the same on record and oblige.

Thanking you,

Yours truly,

For Nectar Lifesciences Limited


Sumit Lal
Company Secretary

Encl. as above

CC:- Societe de la Bourse de Luxembourg S.A.
BP 165, L-2011 Luxembourg,
Telephone : (00352) 47 79 38-1
Fax: (00352) 47 32 98

S. No	PARTICULARS	Quarter ended 31-03-2013	Quarter ended 31-12-2012	Quarter ended 31-03-2012	Year ended 31-03-2013	Year ended 31-03-2012	Year ended 31-03-2013	Year ended 31-03-2012
		Audited (Stand-alone)	Unaudited (Stand-alone)	Unaudited (Stand-alone)	Audited (Stand-alone)	Audited (Stand-alone)	Audited (Consolidated)	Audited (Consolidated)
1.	Income from Operations							
	(a) Gross Sales	38233.34	38095.64	40567.83	167324.71	134173.78	167324.71	134173.78
	Less : Excise Duty	1469.48	1207.10	1188.27	4843.28	3845.02	4843.28	3845.02
	Net Sales	36763.86	36888.54	39379.56	162481.43	130328.76	162481.43	130328.76
	(b) Other Operating Income	10.20	18.85	311.00	143.67	981.84	143.67	981.84
	Total Income from Operations (net)	36774.06	36907.39	39690.56	162625.10	131310.60	162625.10	131310.60
2.	Expenses							
	(a) Cost of Materials consumed	23323.59	30121.56	32435.05	114652.24	97834.97	114652.24	97834.97
	(b) Purchase of Stock in Trade	663.98	845.34	1679.71	5999.80	6302.74	5999.80	6302.74
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(1548.00)	(6041.24)	(5351.91)	(6440.21)	(13466.91)	(6440.21)	(13466.91)
	(d) Employee benefits expense	1498.92	1137.20	1029.97	4861.11	4765.86	4861.11	4765.86
	(e) Depreciation and amortisation expense	1961.03	1922.39	1431.86	7595.61	6072.94	7595.61	6072.94
	(f) Other expenses	4159.99	3649.36	3048.38	14544.15	11018.76	14544.15	11022.18
	Total Expenses	30059.51	31634.61	34273.06	141212.70	112528.36	141212.70	112531.78
3.	Profit from Operations before Other Income, finance costs and exceptional Items (1-2)	6714.55	5272.78	5417.50	21412.40	18782.24	21412.40	18778.82
4.	Other Income	366.61	412.72	372.78	1604.03	1289.40	1604.03	1289.40
5.	Profit before finance costs and exceptional Items (3+4)	7081.16	5685.50	5790.28	23016.43	20071.64	23016.43	20068.22
6.	Finance costs	3470.84	2817.41	3754.96	11548.93	11525.00	11548.93	11525.00
7.	Profit after finance costs but before exceptional Items (5-6)	3610.32	2868.09	2035.32	11467.50	8546.64	11467.50	8543.22
8.	Exceptional Items	0.00	0.00	0.00	0.00	0.00	0.00	0.00
9.	Profit from ordinary activities before tax (7+8)	3610.32	2868.09	2035.32	11467.50	8546.64	11467.50	8543.22
10.	Tax Expense	1046.11	723.46	490.33	2900.95	1221.64	2900.95	1221.64
11.	Net Profit from ordinary activities after tax (9-10)	2564.21	2144.63	1544.99	8566.55	7325.00	8566.55	7321.58
12.	Extraordinary Item (net of tax expense)	0.00	0.00	0.00	0.00	0.00	0.00	0.00
13.	Net Profit for the period (11-12)	2564.21	2144.63	1544.99	8566.55	7325.00	8566.55	7321.58
14.	Paid up Equity Share Capital (Face Value per share : Re. 1/-)	2242.61	2242.61	2242.61	2242.61	2242.61	2242.61	2242.61
15.	Reserves excluding Revaluation Reserves				84,517.96	76,212.05	84,517.96	76,203.71
16.i	Earnings per Share (EPS) (before extraordinary items)							
	a) Basic	1.14	0.96	0.69	3.82	3.27	3.82	3.26
	b) Diluted	1.14	0.96	0.69	3.82	3.27	3.82	3.26
16.ii	Earnings per Share (EPS) (after extraordinary items)							
	a) Basic	1.14	0.96	0.69	3.82	3.27	3.82	3.26
	b) Diluted	1.14	0.96	0.69	3.82	3.27	3.82	3.26

Certified to be true copy

For Nectar Lifesciences Limited

Sunder Lal
Company Secretary

Part II

Select Information for the Quarter and Year Ended 31.03.2013


A	Particulars of shareholding							
1.	Public Shareholding							
	- Number of Shares	124792970	124792970	124792970	124792970	124792970	124792970	124792970
	- Percentage of Shareholding	55.65	55.65	55.65	55.65	55.65	55.65	55.65
2.	Promoters and Promoter Group Shareholding							
	a) Pledged/Encumbered							
	- Number of Shares	0	0	0	0	0	0	0
	- Percentage of Shares (as a % of the total shareholding of promoter and promoter group)	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	- Percentage of Shares (as a % of the total share capital of the company)	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	b) Non-encumbered							
	- Number of Shares	99468000	99468000	99468000	99468000	99468000	99468000	99468000
	- Percentage of Shares (as a % of the total shareholding of promoter and promoter group)	100.00	100.00	100.00	100.00	100.00	100.00	100.00
	- Percentage of Shares (as a % of the total share capital of the company)	44.35	44.35	44.35	44.35	44.35	44.35	44.35

B	Investor Complaints	3 Months ended 31.03.2013						
	Pending at the beginning of Quarter	0						
	Received During the Quarter	12						
	Disposed Off During the Quarter	12						
	Pending at the end of Quarter	0						

Statement of Assets and Liabilities

(Rs in Lacs)

PARTICULARS	As at 31-03-2013	As at 31.03.2012	As at 31-03-2013	As at 31.03.2012
	Audited	Audited	Audited	Audited
	(Stand-alone)	(Stand-alone)	(Consolidated)	(Consolidated)
SHAREHOLDERS' FUND				
(i) Capital	2242.61	2242.61	2242.61	2242.61
(ii) Reserves and Surplus	84517.96	76212.05	84517.96	76203.71
NON CURRENT LIABILITIES				
(i) Long Term Liabilities	26096.08	36361.74	26096.08	36361.74
(ii) Deferred Tax Liability	9575.63	6302.21	9575.63	6302.21
(ii) Other Long Term Liabilities	102.99	195.68	102.99	195.68
(iii) Long Term Provisions	378.88	342.63	378.88	342.63
CURRENT LIABILITIES				
(i) Short Term Borrowings	50911.14	56521.15	50911.14	56521.15
(ii) Trade Payables	38251.85	19449.11	38251.85	19449.11
(iii) Other Current Liabilities	13127.61	12984.3	13127.61	12986.90
(iv) Short Term Provisions	2199.56	1481.37	2199.56	1481.37
	2,27,404.31	2,12,092.85	2,27,404.31	2,12,087.11
NON CURRENT ASSETS				
(i) Fixed Assets (Incl CWIP)	105240.84	100800.54	105240.84	100800.54

Certified to be true copy
For Nectar Lifesciences Limited

Sunder Lal
Company Secretary

- (ii) Non Current Investments
- (iii) Long Term Loans & Advances
- (iv) Other Non Current Assets

CURRENT ASSETS

- (i) Current Investments
- (ii) Inventories
- (iii) Trade Receivables
- (iv) Cash & Bank Balances
- (v) Short Term Loans & Advances
- (vi) Other Current Assets

5.01	5.01	5.01	5.01
7048.61	6318.50	7048.61	6312.20
1.50	2.25	1.50	2.25
31.92	14.11	31.92	14.11
67600.04	59141.59	67600.04	59141.59
34938.64	30449.27	34938.64	30449.27
624.04	2592.48	624.04	2592.48
8684.33	10504.17	8684.33	10504.73
3229.38	2264.93	3229.38	2264.93
2,27,404.31	2,12,092.85	2,27,404.31	2,12,087.11

Notes:

- The above financial results were reviewed by Audit Committee on 14.05.2013 and approved by the Board in its meeting held on 15.05.2013 and further Audited by the Statutory Auditors of the Company.
- The company is exclusively in the pharmaceutical business segment.
- The Board of Directors has recommended the Final Dividend of Re. 0.10/- per equity share (10% on the face value of Re. 1/- per equity share) for the financial year 2012-13, subject to the approval of shareholders at their Annual General Meeting.
- Previous year figures have been regrouped and reclassified wherever necessary to make them comparable with current period.
- The figures of last quarter are the balancing figures between audited figures in respect of the full Financial year and published year to date figures upto third quarter of current financial year.

By Order of the Board of Directors
of Nectar Lifesciences Limited

Sd/-

(Sanjiv Goyal)

Chairman & Managing Director

Dated: 15.05.2013

Place: Chandigarh

Certified to be true copy
For Nectar Lifesciences Limited

Sunder Lal
Company Secretary